Compare FA & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FA | LIVN |
|---|---|---|
| Founded | 2003 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 2021 | 2015 |
| Metric | FA | LIVN |
|---|---|---|
| Price | $20.69 | $78.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $15.67 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 2.5M | 660.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.97 | N/A |
| EPS | 0.11 | ★ 2.33 |
| Revenue | ★ $1,574,389,000.00 | N/A |
| Revenue This Year | $8.42 | $9.79 |
| Revenue Next Year | $7.26 | $6.63 |
| P/E Ratio | $190.00 | ★ $33.79 |
| Revenue Growth | ★ 83.02 | N/A |
| 52 Week Low | $8.82 | $48.82 |
| 52 Week High | $25.15 | $85.76 |
| Indicator | FA | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 46.77 |
| Support Level | $19.05 | $74.99 |
| Resistance Level | $21.42 | $81.83 |
| Average True Range (ATR) | 1.07 | 2.68 |
| MACD | -0.23 | -0.17 |
| Stochastic Oscillator | 11.20 | 49.81 |
First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.